Literature DB >> 33827580

Role of thyroid hormone-integrin αvβ3-signal and therapeutic strategies in colorectal cancers.

Yu-Chen S H Yang1, Po-Jui Ko2,3, Yi-Shin Pan4, Hung-Yun Lin5,6,7,8,9, Jacqueline Whang-Peng10,11, Paul J Davis12,13, Kuan Wang4.   

Abstract

Thyroid hormone analogues-particularly, L-thyroxine (T4) has been shown to be relevant to the functions of a variety of cancers. Integrin αvβ3 is a plasma membrane structural protein linked to signal transduction pathways that are critical to cancer cell proliferation and metastasis. Thyroid hormones, T4 and to a less extend T3 bind cell surface integrin αvβ3, to stimulate the extracellular signal-regulated kinase 1/2 (ERK1/2) pathway to stimulate cancer cell growth. Thyroid hormone analogues also engage in crosstalk with the epidermal growth factor receptor (EGFR)-Ras pathway. EGFR signal generation and, downstream, transduction of Ras/Raf pathway signals contribute importantly to tumor cell progression. Mutated Ras oncogenes contribute to chemoresistance in colorectal carcinoma (CRC); chemoresistance may depend in part on the activity of ERK1/2 pathway. In this review, we evaluate the contribution of thyroxine interacting with integrin αvβ3 and crosstalking with EGFR/Ras signaling pathway non-genomically in CRC proliferation. Tetraiodothyroacetic acid (tetrac), the deaminated analogue of T4, and its nano-derivative, NDAT, have anticancer functions, with effectiveness against CRC and other tumors. In Ras-mutant CRC cells, tetrac derivatives may overcome chemoresistance to other drugs via actions initiated at integrin αvβ3 and involving, downstream, the EGFR-Ras signaling pathways.

Entities:  

Keywords:  Colorectal Cancer; Epidermal growth factor receptor; Integrin αvβ3; NDAT; Ras mutation

Year:  2021        PMID: 33827580     DOI: 10.1186/s12929-021-00719-5

Source DB:  PubMed          Journal:  J Biomed Sci        ISSN: 1021-7770            Impact factor:   8.410


  110 in total

1.  Gefitinib in colorectal cancer: if wishes were horses.

Authors:  Charles D Blanke
Journal:  J Clin Oncol       Date:  2005-08-20       Impact factor: 44.544

2.  Thyroxine inhibits resveratrol-caused apoptosis by PD-L1 in ovarian cancer cells.

Authors:  Yu-Tang Chin; Po-Li Wei; Yih Ho; André Wendindondé Nana; Chun A Changou; Yi-Ru Chen; Yu-Chen Sh Yang; Meng-Ti Hsieh; Aleck Hercbergs; Paul J Davis; Ya-Jung Shih; Hung-Yun Lin
Journal:  Endocr Relat Cancer       Date:  2018-03-19       Impact factor: 5.678

Review 3.  Molecular aspects of thyroid hormone actions.

Authors:  Sheue-Yann Cheng; Jack L Leonard; Paul J Davis
Journal:  Endocr Rev       Date:  2010-01-05       Impact factor: 19.871

Review 4.  Targeting Krasg12c -mutant cancer with a mutation-specific inhibitor.

Authors:  J G Christensen; P Olson; T Briere; C Wiel; M O Bergo
Journal:  J Intern Med       Date:  2020-04-07       Impact factor: 8.989

5.  Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer.

Authors:  Rafael G Amado; Michael Wolf; Marc Peeters; Eric Van Cutsem; Salvatore Siena; Daniel J Freeman; Todd Juan; Robert Sikorski; Sid Suggs; Robert Radinsky; Scott D Patterson; David D Chang
Journal:  J Clin Oncol       Date:  2008-03-03       Impact factor: 44.544

Review 6.  Molecular mechanisms of resistance to cetuximab and panitumumab in colorectal cancer.

Authors:  Alberto Bardelli; Salvatore Siena
Journal:  J Clin Oncol       Date:  2010-01-25       Impact factor: 44.544

Review 7.  Diverse mechanisms for activation of Wnt signalling in the ovarian tumour microenvironment.

Authors:  Maria V Barbolina; Rebecca J Burkhalter; M Sharon Stack
Journal:  Biochem J       Date:  2011-07-01       Impact factor: 3.857

8.  Atorvastatin overcomes gefitinib resistance in KRAS mutant human non-small cell lung carcinoma cells.

Authors:  J Chen; H Bi; J Hou; X Zhang; C Zhang; L Yue; X Wen; D Liu; H Shi; J Yuan; J Liu; B Liu
Journal:  Cell Death Dis       Date:  2013-09-26       Impact factor: 8.469

9.  Enhancement by Nano-Diamino-Tetrac of Antiproliferative Action of Gefitinib on Colorectal Cancer Cells: Mediation by EGFR Sialylation and PI3K Activation.

Authors:  Tung-Cheng Chang; Yu-Tang Chin; André Wendindondé Nana; Shwu-Huey Wang; Yu-Min Liao; Yi-Ru Chen; Ya-Jung Shih; Chun A Changou; Yu-Chen Sh Yang; Kuan Wang; Jacqueline Whang-Peng; Liang-Shun Wang; Steven C Stain; Ai Shih; Hung-Yun Lin; Chih-Hsiung Wu; Paul J Davis
Journal:  Horm Cancer       Date:  2018-09-05       Impact factor: 3.869

Review 10.  The Roles of Thyroid and Thyroid Hormone in Pancreas: Physiology and Pathology.

Authors:  Chaoran Chen; Zhenxing Xie; Yingbin Shen; Shu Fang Xia
Journal:  Int J Endocrinol       Date:  2018-06-14       Impact factor: 3.257

View more
  6 in total

Review 1.  The Clinical Relevance of Hypothyroidism in Patients with Solid Non-Thyroid Cancer: A Tantalizing Conundrum.

Authors:  Maria V Deligiorgi; Dimitrios T Trafalis
Journal:  J Clin Med       Date:  2022-06-14       Impact factor: 4.964

2.  Role of Integrin αvβ3 in Doxycycline-Induced Anti-Proliferation in Breast Cancer Cells.

Authors:  Yi-Fong Chen; Yung-Ning Yang; Hung-Ru Chu; Tung-Yung Huang; Shwu-Huey Wang; Han-Yu Chen; Zi-Lin Li; Yu-Chen S H Yang; Hung-Yun Lin; Aleck Hercbergs; Jacqueline Whang-Peng; Kuan Wang; Paul J Davis
Journal:  Front Cell Dev Biol       Date:  2022-02-14

Review 3.  Toxicologic Concerns with Current Medical Nanoparticles.

Authors:  Tsai-Mu Cheng; Hsiu-Yi Chu; Haw-Ming Huang; Zi-Lin Li; Chiang-Ying Chen; Ya-Jung Shih; Jacqueline Whang-Peng; R Holland Cheng; Ju-Ku Mo; Hung-Yun Lin; Kuan Wang
Journal:  Int J Mol Sci       Date:  2022-07-08       Impact factor: 6.208

Review 4.  The power of heteronemin in cancers.

Authors:  Kuan Wang; Yi-Fong Chen; Yu-Chen S H Yang; Haw-Ming Huang; Sheng-Yang Lee; Ya-Jung Shih; Zi-Lin Li; Jacqueline Whang-Peng; Hung-Yun Lin; Paul J Davis
Journal:  J Biomed Sci       Date:  2022-06-15       Impact factor: 12.771

5.  Ginsenoside Rh3 Inhibits Lung Cancer Metastasis by Targeting Extracellular Signal-Regulated Kinase: A Network Pharmacology Study.

Authors:  Xiaodan Xue; Yannan Liu; Linlin Qu; Cuiying Fan; Xiaoxuan Ma; Pingkai Ouyang; Daidi Fan
Journal:  Pharmaceuticals (Basel)       Date:  2022-06-17

Review 6.  Thyroid hormones act as modulators of inflammation through their nuclear receptors.

Authors:  Marina Lasa; Constanza Contreras-Jurado
Journal:  Front Endocrinol (Lausanne)       Date:  2022-08-08       Impact factor: 6.055

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.